Genomed

Genomed Liabilities

The The Liabilities of Genomed (GEN.WA) as of Nov 20, 2026 is 2.41 M PLN. In the previous year, The Liabilities was 1.68 M PLN — a change of 43.37% (higher).

Liabilities

2.41 MPLN

YoY

43.37%

Last updated:

In 2025, Genomed's total liabilities amounted to 2.41 M PLN, a 43.37% difference from the 1.68 M PLN total liabilities in the previous year.

The Genomed Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
1.77 M PLN
Jan 1, 2019
1.75 M PLN
Jan 1, 2020
2.45 M PLN
Jan 1, 2021
1.53 M PLN
Jan 1, 2022
1.24 M PLN
Jan 1, 2023
2.06 M PLN
Jan 1, 2024
1.68 M PLN
Jan 1, 2025
2.41 M PLN
The Genomed Liabilities history
YEARLiabilitiesYoY
2.41 MPLN+43.37%
1.68 MPLN-18.44%
2.06 MPLN+65.92%
1.24 MPLN-18.98%
1.53 MPLN-37.49%
2.45 MPLN+40.44%
1.75 MPLN-1.38%
1.77 MPLN-29.42%
2.51 MPLN-8.20%
2.73 MPLN+24.89%
2.19 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomed Stock analysis

What does Genomed do? Genomed SA generates revenue through molecular diagnostics services based on DNA sequencing, particularly Next Generation Sequencing (NGS). The company offers gene mutation analysis for over 150 congenital diseases including infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. Their primary clients are healthcare providers and research institutions seeking personalized medicine solutions and genomic technology integration. Genomed SA also provides DNA sequencing, analysis, and synthesis services for the biotechnological market, targeting academic and industrial research sectors. The company's business model focuses on developing advanced diagnostic tools for medical applications, with a strong emphasis on NGS technology. Their service portfolio includes specialized genetic testing for congenital conditions and research-oriented DNA services. By concentrating on personalized medicine and gene treatment clinics, Genomed SA positions itself as a provider of specialized genomic solutions for both clinical and research markets. Genomed SA's revenue streams are derived from diagnostic testing services for congenital diseases and biotechnological DNA services. The company serves healthcare facilities requiring genetic analysis for patient care and research organizations needing genomic data for scientific advancement. Their offerings target medical professionals and biotechnology companies seeking to implement genomic technology in their operations. Genomed is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Genomed's Liabilities

Genomed's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Genomed's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Genomed's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Genomed's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Genomed’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Genomed stock

The Liabilities of Genomed is 2.41 M PLN in 2025.

The Liabilities of Genomed changed from 1.68 M PLN to 2.41 M PLN, representing a 43.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Genomed since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Genomed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genomed

All Key Metrics — Genomed